USPTO Examiner LU CHENG - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18758038Trispecific T cell EngagersJune 2024December 2025Allow1721YesNo
18628224USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENTApril 2024December 2025Abandon2020NoNo
18622066Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid TumorsMarch 2024October 2025Allow1911YesNo
18600481BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOFMarch 2024December 2025Allow2111NoNo
18545890CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCERDecember 2023September 2025Abandon2110NoNo
18481291METHODS OF TREATING HER2-POSITIVE CANCEROctober 2023June 2024Abandon800NoNo
18452972METHODS OF TREATING CANCERAugust 2023May 2025Abandon2111NoNo
18323898COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLSMay 2023March 2025Abandon2211NoNo
18181661IMMUNOSTIMULATORY AGONISTIC ANTIBODIES FOR USE IN TREATING CANCERMarch 2023October 2024Abandon1901NoNo
18160202NIR-CONJUGATED TUMOR-SPECIFIC ANTIBODIES AND USES THEREOFJanuary 2023August 2024Allow1921YesNo
18154295METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASISJanuary 2023November 2024Abandon2211NoNo
18153286MODIFIED ANTIBODY-ALBUMIN NANOPARTICLE COMPLEXES FOR CANCER TREATMENTJanuary 2023October 2025Abandon3331NoNo
18090570COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCERDecember 2022June 2025Abandon2911NoNo
17991775NOVEL ANTIBODIES AND METHODS FOR MAKING AND USING THE SAMENovember 2022October 2024Allow2311YesNo
18056711HUMAN PD-L1 ANTIBODIES AND METHODS OF USE THEREFORNovember 2022February 2025Allow2711YesNo
18054347ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINENovember 2022January 2025Abandon2621NoNo
17975508ANTIBODIES SPECIFIC FOR GUCY2C AND USES THEREOFOctober 2022December 2024Allow2511NoNo
17917513Monoclonal Antibodies and Antigen Binding Fragments Thereof for Suppressing CD73 Immune Checkpoint and Uses ThereofOctober 2022March 2026Allow4111YesNo
17932986COMBINATION THERAPYSeptember 2022August 2023Abandon1101NoNo
17823640METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH ACTIVATION OF THE MAPK PATHWAYAugust 2022March 2025Abandon3131NoNo
17820624RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2August 2022December 2025Abandon4010NoNo
17818907INHIBITORS OF EPHRIN B1 FOR TUMOR TREATMENTAugust 2022March 2024Abandon1901NoNo
17883158BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOFAugust 2022November 2023Allow1510NoNo
17815514ANTI-CD46 ANTIBODIES AND METHODS OF USEJuly 2022November 2024Allow2721YesNo
17859078PEPTIDE-LIPOSOME COMPLEX FOR MULTIVALENT CROSSLINKING WITH PD-L1 AND COMPOSITION INCLUDING THE SAMEJuly 2022February 2026Abandon4321NoNo
17853606Novel Monoclonal Antibodies to Programmed DEATH (PD-1)June 2022January 2024Abandon1811NoNo
17808964COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDESJune 2022March 2026Abandon4501NoNo
17786717COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROMEJune 2022January 2026Abandon4301NoNo
17830817METHODS OF TREATING CANCER WITH AN ANTI-CD39 ANTIBODY AND PEMBROLIZUMABJune 2022July 2024Abandon2511NoNo
17747886USES OF ANTI-ICOS ANTIBODIESMay 2022February 2026Abandon4541NoNo
17738191MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOFMay 2022November 2023Allow1821NoNo
17719609CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCERApril 2022September 2023Allow1711YesNo
17718888METHODS OF TREATING CANCERApril 2022October 2023Abandon1811NoNo
17768290METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH CAPECITABINE AND TRASTUZUMABApril 2022December 2025Abandon4410NoNo
17768455COMBINATION THERAPY FOR TREATMENT OF CANCERSApril 2022November 2025Abandon4301NoNo
17714724METHODS OF TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA USING TELISOTUZUMAB VEDOTINApril 2022May 2025Allow3740YesYes
17766450FUSION PROTEIN, AND PREPARATION METHOD AND USE THEREOFApril 2022September 2025Allow4210YesNo
17656698AFFINITY MATURATED TAG72 SPECIFIC SINGLE CHAIN ANTIBODIESMarch 2022January 2026Allow4511YesNo
17692006METHODS OF TREATING CANCERMarch 2022October 2023Abandon1911NoNo
17691645DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 (HER3) MONOCLONAL ANTIBODIES TO TREAT TUMORS ASSOCIATED WITH NEUREGULIN 1 (NRG1) GENE FUSIONSMarch 2022August 2025Abandon4101NoNo
17686565THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCERMarch 2022July 2025Abandon4020NoNo
17652709ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCERFebruary 2022October 2023Allow2011YesNo
17670413METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTSFebruary 2022June 2024Abandon2811NoNo
17667901CREBBP RELATED CANCER THERAPYFebruary 2022April 2024Abandon2611NoNo
17666424METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASESFebruary 2022February 2025Abandon3621NoNo
17583521ANTI-PD-L1 ANTIBODIES AND VARIANTSJanuary 2022November 2022Allow1000YesNo
17629139INHIBITORS OF CHI3L1 AND THEIR USESJanuary 2022February 2026Abandon4921NoNo
17575246NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIESJanuary 2022April 2024Allow2711YesNo
17571430METHODS OF CANCER TREATMENT USING TUMOR ANTIGEN-SPECIFIC T CELLSJanuary 2022June 2022Allow510YesNo
17563866METHODS FOR TREATING CANCERS WITH MODIFIED PBMCSDecember 2021December 2025Abandon4741NoNo
17620395COMPOSITIONS AND METHODS TARGETING THE NUCLEOTIDE FREE STATE OF RAS TO BLOCK ONCOGENIC SIGNALING AND TRANSFORMATIONDecember 2021October 2025Allow4621YesNo
17554682COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIESDecember 2021August 2025Allow4431YesNo
17550276Compositions and Methods for the Treatment of Cancer (Anti-ICOS Antibody Dosing)December 2021June 2023Abandon1810NoNo
17615863ANTI-PSGL-1 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOFDecember 2021October 2025Allow4611YesNo
17535004AMHRII-BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCERSNovember 2021January 2025Abandon3841NoNo
17525898Methods and agents to treat tumor cells and cancerNovember 2021May 2024Abandon3021NoNo
17524049METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A PD-L1 BINDING ANTAGONIST FOR TREATING LUNG CANCERNovember 2021August 2024Allow3431NoNo
17609641GLYCOPEPTIDE VACCINENovember 2021September 2025Abandon4601NoNo
17519327Combinations of Cabozantinib and Atezolizumab to Treat CancerNovember 2021November 2024Abandon3630NoNo
17518272MODULATING GABARAP TO MODULATE IMMUNOGENIC CELL DEATHNovember 2021February 2024Allow2721YesNo
17509028Methods, agents and compositions as in situ vaccine for cancer cell and tumor treatmentOctober 2021March 2026Abandon5221NoNo
17605331SYSTEMS AND METHODS FOR MODULATING A CELL PHENOTYPEOctober 2021June 2025Abandon4411NoNo
17599179CANCER BIOMARKERS FOR DURABLE CLINICAL BENEFITSeptember 2021June 2025Abandon4511NoNo
17442640SUBSTANCE INTERACTING WITH C TERMINAL FRAGMENT OF THE STIM1 FRACTION LOCALIZED TO THE PLASMA MEMBRANE OF THE CELLS, FOR ITS USE IN THE TREATMENT OF CANCERS, AND IN SCREENING AND DIAGNOSTIC METHODSSeptember 2021November 2025Abandon5021NoNo
17438545TARGETING REGULATORY B CELLS AND THEIR REGULATORS FOR CANCER IMMUNOTHERAPYSeptember 2021December 2025Abandon5111NoNo
17468115LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIESSeptember 2021June 2025Abandon4611NoNo
17435561MRNA VACCINESeptember 2021December 2025Abandon5221NoNo
17407404RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2August 2021December 2022Abandon1520YesNo
17404717PANCREATIC CANCER DETECTION METHOD AND PANCREATIC CANCER DETECTION KITAugust 2021September 2023Allow2511YesNo
17427545ANTIBODY AND FUNCTIONAL FRAGMENT THEREOFJuly 2021March 2025Allow4320YesNo
17387223ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAMEJuly 2021July 2025Allow4731YesNo
17424964BINDER AGAINST PROGRAMMED DEATH-LIGAND AND APPLICATION THEREOFJuly 2021February 2025Allow4320YesNo
17357380Combination Therapy for CancerJune 2021March 2025Abandon4401NoNo
17413260ANTIBODY-TNF alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONSJune 2021February 2025Allow4411YesNo
17312019IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATEJune 2021April 2025Allow4621YesNo
17338149ANTI-CD70 ANTIBODIES AND USES THEREOFJune 2021April 2024Allow3521NoNo
17329075[6R]-MTHF - an efficient folate alternative in 5-fluorouracil based chemotherapyMay 2021September 2025Allow5221YesNo
17320996Immune Monitoring of Neuro-Inflammatory Amyotrophic Lateral Sclerosis (ALS)May 2021September 2025Allow5221NoNo
17294345METHODS OF SELECTING FUNCTIONAL INTERFACE MIMICS, AND COMPOSITIONS THEREOFMay 2021November 2024Abandon4201NoNo
17294008AGONISTIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDESMay 2021May 2025Allow4821YesNo
17291303FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOFMay 2021February 2026Abandon5821YesNo
17290180ANTI-HUMAN Fn14 ANTIBODYApril 2021September 2024Allow4110YesNo
17289389METHODS OF TREATING CANCERApril 2021April 2024Abandon3511NoNo
17289204CRISPR/CAS12F ENZYME AND SYSTEMApril 2021March 2026Allow5941YesNo
17238599ACTIVITY SENSOR CONTROLSApril 2021December 2024Abandon4421NoNo
17285470MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND USES THEREOFApril 2021December 2024Allow4420YesNo
17284119ANTI-MERTK ANTIBODIES FOR TREATING CANCERApril 2021February 2025Abandon4611NoNo
17281724PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIESMarch 2021October 2025Abandon5420NoNo
17275974RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPYMarch 2021October 2024Allow4321YesNo
17187511BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOFFebruary 2021December 2023Allow3321YesNo
17271500PLK1 TARGET PHOSPHORYLATION STATUS AND TREATMENT OF CANCER WITH PLK1 INHIBITORSFebruary 2021February 2026Allow5940YesNo
17184360MOLECULAR BIOMARKERS AND TARGETS FOR FUCHES' ENDOTHELIAL CORNEAL DYSTROPHY AND GLAUCOMAFebruary 2021December 2025Allow5861YesNo
17266883CANCER TREATMENT WITH AN ANTIBODYFebruary 2021October 2023Allow3210YesNo
17265755EPITOPE OF EPB41L5, AND MONOCLONAL ANTIBODYFebruary 2021March 2025Allow4921YesNo
17164696Trispecific T cell EngagersFebruary 2021March 2024Allow3811YesNo
17154889COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLSJanuary 2021August 2023Abandon3111NoNo
17254433COMPOSITIONS AND METHODS FOR PROTEIN LABELING, MODIFICATION, ANALYSIS, AND TARGETED DELIVERYDecember 2020September 2024Allow4511YesNo
17252035COMPOSITION FOR DIAGNOSIS OF BONE METASTASIS OF CANCER AND KIT COMPRISING SAMEDecember 2020March 2025Abandon5130NoNo
16972404INHIBITORS OF SHP2December 2020June 2024Abandon4301NoNo
17059995PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITORNovember 2020November 2024Abandon4831YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LU, CHENG.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
4
(100.0%)
Filing Benefit Percentile
0.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LU, CHENG - Prosecution Strategy Guide

Executive Summary

Examiner LU, CHENG works in Art Unit 1642 and has examined 174 patent applications in our dataset. With an allowance rate of 56.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner LU, CHENG's allowance rate of 56.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LU, CHENG receive 1.95 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LU, CHENG is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +69.5% benefit to allowance rate for applications examined by LU, CHENG. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.1% of applications are subsequently allowed. This success rate is in the 46% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.8% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 18.2% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.